- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00165984
Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
In the United States, approximately 30,000 children are born with congenital heart disease every year. Between 1000 and 2000 of these children have some form of functional single ventricle anatomy, with variants of hypoplastic left heart syndrome (HLHS) comprising about half. Patients with functional single ventricle anatomy are born with a malformation that renders one of their ventricles unusable and surgically unrecoverable. In HLHS, for example, either the mitral or aortic valve can be absent or significantly stenotic, which is generally associated with marked hypoplasia of the left ventricle and the ascending aorta. Other common variants of single ventricle anatomy are tricuspid or pulmonary atresia, often associated with some degree of right ventricular hypoplasia, unbalanced atrioventricular defects, in which either ventricle can be unusable due to malposition of the interventricular septum, and the heterotaxy syndromes. All of these congenital cardiac anomalies, as well as several other less common variants, can be treated with a multi-stage surgical palliation that usually requires three surgical procedures during the first three years of life. At the completion of this series of palliative procedures the children are left with their single functional ventricle driving blood flow to the systemic circulation while their pulmonary circulation is derived from passive drainage of the systemic venous return into and through the pulmonary vasculature. This arrangement, the so-called "Fontan physiology", can provide an excellent quality of life as these children grow and enter young adulthood; however, it is by no means a normal hemodynamic arrangement and a significant percentage of children with single ventricle anatomy will fail either during the early palliative steps or at some point after they achieve final Fontan palliation.
Failure of single ventricle patients to progress through the multi-stage palliation or late failure of patients after the Fontan procedure can result from a myriad of causes. While ventricular dysfunction is a common finding in failing single ventricle patients, an anatomic reason for their clinical failure, such as myocardial ischemia or ventricular outflow obstruction, often cannot be identified. Many of these patients subsequently die or require cardiac transplantation when their single ventricle fails. Because patient outcomes are highly variable despite similar anatomy and hemodynamics, it has been suggested that genetic variability may play a role in the ability of patients to tolerate long-term single ventricle palliation.
The interaction between genetic variability and outcomes has been well documented for adult patients with cardiovascular disease. Genetic polymorphisms in the renin-angiotensin system (RAS) in particular have been well studied. The active final product of the RAS is angiotensin-II, which is produced by the sequential cleavage of angiotensinogen (AGT) by renin and angiotensin-converting enzyme (ACE). Several steps in this series of enzymatic reactions have been evaluated as candidate genes of influence for cardiovascular disorders.
Polymorphisms in the AGT gene have been associated with essential hypertension, however, a subsequent study failed to demonstrate any influence of these polymorphisms on outcome in patients with idiopathic dilated cardiomyopathy. A polymorphism in the ACE gene involving a 287-base pair insertion (I) or deletion (D) has been evaluated in several studies. The DD genotype is associated with higher serum levels of ACE and angiotensin II, increased incidence of sudden death in patients with hypertrophic cardiomyopathy, increased mortality in patients with idiopathic heart failure, and decreased exercise tolerance in patients with congestive heart failure. Meanwhile, a genetic variant in the Angiotensin II type 2-receptor (AT2-R) has been shown to influence left ventricular structure and function in young men with hypertension.
Another potentially important contributor to ventricular function that has been studied with regard to genetic polymorphism related variability is the Beta1-adrenergic receptor (Beta1-AR). The Beta1-AR is the primary myocardial receptor for the catecholamines epinephrine and norepinephrine, which increase myocardial contractility and blood pressure. Several polymorphisms in the Beta1-AR gene have been associated with an increased risk for congestive heart failure and with exercise capacity in patients with ischemic or idiopathic cardiomyopathy.
A final area of interest is the opposing system of vasodilators and vasoconstrictors that control systemic vascular tone. Two major contributors to vasomotor tone in humans are the endothelium derived vasodilator nitric oxide (NO) and the powerful vasoconstrictor endothelin-1. Endothelial NO is produced by the enzyme endothelial nitric oxide synthase (eNOS). A single base-pair polymorphism (G894T) is associated with an increased risk of vasospastic angina pectoris and with increased vascular responsiveness to phenylephrine in patients on cardiopulmonary bypass. Meanwhile, a single base-pair polymorphism in the preproendothelin-1 (pp-ET1) gene (G5665T) has been shown to increase vasomotor reactivity in human mammary arteries. This polymorphism is also associated with hypertension in overweight patients with the T allele.
While there is very little data available regarding the causes of failure in children with single ventricle anatomy, it is clear that genetic factors which influence ventricular function and the development of heart failure in adults with two ventricles could play a role in the failure of patients with one ventricle. We propose a combined retrospective and prospective evaluation of each of the candidate gene polymorphisms discussed above for potential linkage to poor outcome in children with single ventricle anatomy. Poor outcome for these children would be defined as a multi-endpoint variable including death, evaluation for heart transplantation, or the development of severe single ventricle dysfunction by echocardiographic or cardiac catheterization criteria. Identification of high-risk combinations of genetic alleles could guide therapy for patients with poor predicted outcome, possibly steering such patients towards early transplantation rather than attempted staged palliation.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Children's Healthcare of Atlanta at Egleston
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Children who currently have functional single ventricle anatomy or have had heart transplantation for single ventricle anatomy who receive their cardiac care at Children's Healthcare of Atlanta, Egleston Hospital.
- Family agrees to participate in the study following informed consent
Exclusion Criteria:
- Conversion to two ventricle physiology, excluding transplantation.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
To Evaluate the Incidence of the Pre-proendothelin SNP at Nucleotide 5665
Lasso di tempo: 7 years
|
7 years
|
|
Survival
Lasso di tempo: 7 yr mean follow-up
|
Follow-up study designed to determine the impact of genetic factors on survival in single ventricle patients
|
7 yr mean follow-up
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Paul M Kirshbom, MD, Emory University
Pubblicazioni e link utili
Pubblicazioni generali
- Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993 Oct 30;342(8879):1085-6. doi: 10.1016/0140-6736(93)92064-z.
- Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002 Oct 10;347(15):1135-42. doi: 10.1056/NEJMoa020803.
- Iglarz M, Benessiano J, Philip I, Vuillaumier-Barrot S, Lasocki S, Hvass U, Durand G, Desmonts JM, Levy BI, Henrion D. Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro. Hypertension. 2002 Feb;39(2):209-13. doi: 10.1161/hy0202.103442.
- Wagoner LE, Craft LL, Zengel P, McGuire N, Rathz DA, Dorn GW 2nd, Liggett SB. Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J. 2002 Nov;144(5):840-6. doi: 10.1067/mhj.2002.125325.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 599-2004
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cardiopatia congenita
-
Region SkaneIscrizione su invitoInsufficienza cardiaca Classe II della New York Heart Association (NYHA). | Insufficienza cardiaca Classe III della New York Heart Association (NYHA).Svezia
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University... e altri collaboratoriNon ancora reclutamentoInsufficienza cardiaca, sistolica | Insufficienza cardiaca con frazione di eiezione ridotta | Scompenso cardiaco Classe IV della New York Heart Association | Scompenso cardiaco Classe III della New York Heart AssociationPolonia
-
University of WashingtonAmerican Heart AssociationCompletatoInsufficienza cardiaca, congestizia | Alterazione mitocondriale | Scompenso cardiaco Classe IV della New York Heart AssociationStati Uniti